Electronic voting will take place from March 31 to April 14, 2025 for the positions of Vice President and Regional Director, Ontario. Results will be announced on April 22, 2025.

Below is the list of nominees and the position for which they have been nominated.

Dr. Nicole Maillet-Lebel – Vice President (Election)

Dr Maillet-Lebel

 

 

Present Affiliations

Academic

  • Clinical Assistant Professor Memorial University
  • Clinical Assistant Professor Dalhousie University
  • ClinicalAssistant Professor Université de Sherbrooke

Clinical

  • Horizon Health Network – Moncton
  • Hospital Réseau de santé Vitalité – George L. Dumont University Hospital

Other National, Provincial and Local Dermatology Societies 

  • DRIVE executive committee, incoming co-chair (2024-2025)
  • DRIVE executive committee, co-chair (2025-2026)
  • Atlantic Provinces Dermatology Association, planning committee for the annual conference (2023-2024)

Medical Society, Governmental and/or Professional Appointments, Awards and Honours

  • Owner and Medical Director of Corium Medical Dermatology in Moncton (NB)
  • French Dermatology Society bursary, Paris (France), December 2016

Number of Publications Authored

4

List of Publications Authored

  • Maillet-Lebel, Thibeault, « Intralesionnal Rituximab for Cutaneous Manifestations of Systemic B-cellLymphoma », JAAD case reports, July 2016
  • Maillet-Lebel, Kokta, Coulombe, Powel, « A case of segmental stiffskin syndrome treated with systemic losartan », Pediatric Dermatology, January 2018
  • Lim, Audessat, Maillet-Lebel, Marcoux, « Flagellate dermatitis in a child most likely secondary to Doxorubicin », PediatricDermatology, September 2017
  • Dominique Comeau, Veronique Allain, Nicole Maillet-Lebel, Mouna Ben Amor« Novel dermatological and skeletal features associated to PTEN variant in PTEN hamartoma tumor syndrome »,European Journal of Medical Genetics, June 2023

Other Professional/Academic Activities 

  • Teaching the dermatology segment at Sherbrooke University, Moncton campus, 2021-2024 Facebook Live interview on Atopic dermatitis, Reader’s Digest, Fall 2022
  • Live radio interview on Vitiligo, Radio Canada, Fall 2020
  • Conference presentations:
    • New Brunswick Internal Medicine annual conference in April 2024 and April 2022
    • « Rash 101 » for the annual Nurse Practitioner conference at Universite de Moncton, May 2021
    • General Dermatology class for Family medicine residents at Sherbrooke University, Moncton Campus,December 2019 and 2022
    • « A case of segmental stiff skin syndrome treated with systemic Losartan », presented at theCanadian Dermatology Association conference, Spring 2017
    • « Flagellate dermatitis in a child, most likely secondary to Doxorubicin », presented at the American Academy of Dermatology, Spring 2017
    • Case presentations at the Atlantic Provinces Dermatology Association conference in June 2015 andJune 2016
    • Case presentations at the Quebec Dermatology Society Annual meeting, May 2016 and June 2017
Dr. Youwen Zhou – Vice President (Election)

Dr. Zhou

 

Present Affiliations

Academic

  • Professor, Department of Dermatology and Skin Science, University of British Columbia

Clinical

  • Dermatology private practice, Vancouver Skin Care Centre
  • Consultant dermatologist, Vancouver General Hospital
  • Consultant Dermatologist, St Paul’s Hospital
  • Dermatologic oncologist, British Columbia Cancer Agency

CDA Involvement

  • Board of Directors, Canadian Dermatology Association, 2020-2022
  • Regional Director for British Columbia, 2020-2022
  • Finance & Audit Committee, Canadian Dermatology Association 2020-2022
  • CDA Symposium Director for CSID at Annual Conference, 2005-2018
  • CDA Annual Conference Moderator, WCD-CDF Lectureship, 2024-present
  • CDF50 Celebration Coordinator at CDA Annual Conference, 2019
  • Chair, CDA Workshop on Grantsmanship, 2019
  • Mentor, CDA Young Dermatologist Network Session, 2018
  • CDA Annual Conference Session Chair, 60 tips in 60 minutes, 2016
  • Member, CDA Membership and Awards Committee 2005 – 2007
  • Editorial board member, Journal of Cutaneous Medicine and Surgery, 2001 – present
  • CDA Media speaker on sun safety and skin disease prevention, 2005 – 2006
  • CDA Representative, IMHA Institute Advisory Board of Canadian Institutes of Health Research (IMHA Institute), 2010 – 2015

Other National, Provincial and Local Dermatology Societies

  • Canadian Dermatology Foundation, President, 2023-present
  • Canadian Dermatology Foundation, Executive Board Member & Secretary, 2016 – 2023
  • Canadian Melanoma Foundation, President, 2008 – 2020
  • President, Canadian Society of Investigative Dermatology (CSID), 2005-2013
  • Secretary, Canadian Society of Investigative Dermatology, 2013 – present
  • ca, Board Member, 2010 – present
  • North American Chinese Dermatology Association, President, 2018
  • World Vitiligo Working Group, Basic Science Committee Member, 2013 – present International Society of Cutaneous Lymphoma, Membership Committee, 2010 – present
  • World Vitiligo Conference, Scientific Advisory Committee Member, 2016 -present Dermatology World Congress, Bidding Committee Member, 2010 – 2015
  • American Academy of Dermatology, Poster Task Force Member, 2007 – 2010
  • Pan American Society of Pigment Cell Research, Awards & Nominations Committee Member, 2011 – 2015
  • American Academy of Dermatology (AAD), Director, Focused session on Skin Pigmentation Disorders, Annual Conference, 2005 – 2007

Medical Society, Governmental and/or Professional Appointments, Awards and Honours

Awards and Honours with CDA:

  • CDA Research Award, Canadian Dermatology Association 2012
  • CDF Lecturer of the Year, Canadian Dermatology Association, 2007

Other Awards and Honours:

  • Michael Smith Health Professional Investigator Award, 2023
  • Henry Fok Award of Medicine, 2020
  • Pro-patient Dermatologist, Recognition, Canadian Skin Patient Alliance, 2015
  • Dermatology Research Impact Story of the Year, Canadian Institutes of Health Research, 2013
  • Established Clinician Scientist Award, Vancouver General Hospital “In it for Life Foundation”, 2007
  • Leo Award, Canadian Dermatology Foundation, 2005
  • Medicine Scholar Award, Faculty of Medicine, University of British Columbia, 2002, 2003, 2004, and 2005
  • New Opportunity Research Award, Canadian Foundation for Innovation, 2004
  • New Investigator Award, Banting Research Foundation, 2002
  • Young Investigator Award, Canadian Dermatology Foundation, 2002
  • UBC-Galderma Dermatology Award, University of British Columbia, 2002
  • Department of Medicine Career Development Award, University of British Columbia, 2001
  • MRC Networks of Centres of Excellence Postdoctoral Award, Medical Research Council of Canada, 1990 – 1993
  • Stephen Morse Award for Outstanding Achievements in Graduate Research, State University of New York, USA, 1989

Other Professional/Academic Activities

  • Federal Ministry of Health Canada, Dermatology expert panel Member, 2009 – present
  • Winter Olympics Medical Committee, Dermatology Lead , 2010
  • British Columbia Cancer Agency, Skin Cancer Management Guidelines Committee Member, 2007 – present
  • University of British Columbia, Personalized Medicine Initiative Member, 2010 – present
  • British Columbia Cancer Agency, Personalized Oncogenomics (POG) Program, Member, 2013 – present
  • University of British Columbia, Faculty of Medicine, MD- PhD Program, Scientific Committee member. 2009-2013
  • University of British Columbia, Volunteer for multiple mini-interviews for Undergraduate Medical Admissions, 2020, 2023 Conference /Symposium

Conference Organizing and Planning:

  • Chair, Annual Symposia of Canadian Society of Investigative Dermatology, Canada, 2007 to 2013
  • Planning committee member, CDF 50 Celebrations Program, Canadian Dermatology Association, Calgary, Canada, 2019
  • 16th Pan American Society of Pigment Cell Research Annual Meeting (Conference chair, and Chair of the Organizing Committee), Vancouver, Canada, 2010
  • Organizing Committee member, UBC Annual Skin Research Day, Vancouver, Canada, 2010-present
  • Conference chair, Symposium of International Society of Cutaneous Lymphoma, Vancouver, Canada, 2015
  • Session Chair, World Congress of Dermatology Symposium on Hyperhidrosis and hypohidrosis, Vancouver, Canada, 2015
  • Session Chair, World Congress of Dermatology Symposium on Hyperhidrosis and hypohidrosis, Milan, Italy, 2019
  • Conference chair and program director, Dermatology International Summit, Vancouver, Canada, 2015
  • Chair of Organizing Committee, International Symposium on Clinical Dermatology, Shanghai, China, 2017
  • Chair of Organizing Committee, Research Progresses in Translational Dermatology, Shanghai, China, 2017
  • Chair of Organizing Committee, NACDA International Symposium of Clinical and Investigational Dermatology, Orlando, Florida, USA, 2017
  • Chair of Organizing Committee, NACDA International Symposium of Clinical and Investigational Dermatology, San Diego, California, USA, 2018
  • Chair or organizing committee, Grantsmanship workshop, Canadian Dermatology Association, Calgary, 2019
  • Symposium organizer, Canadian Society of Investigative Dermatology at CDA, 2005- 2018

Advocacy for Supporting Canadian Dermatology Research:

  • Over 15 years working with Canadian Dermatology Foundation (first as the executive board member and Scientific Chair, and currently the President), I helped raise >5 million dollars of funds to support dermatologist researchers across Canada, 2007- present
  • As the member of Institute Advisory Board (IAB) for Canadian Institutes of Health Research (CIHR-IMHA, 2012-2017), representing the Canadian dermatology community, I was the primary advocate for a number of initiatives that resulted in two major network catalyst grants totalling more than $2 million for skin research community in Canada

Patient Advocacy:

  • Project Lead, Patient, Public and Community (PPC) Engagement in dermatologic therapeutic research in British Columbia, 2023-present
  • Physician Supporter for Canadian Skin Patient Alliance Recognition (CSPA), 2018
  • Conference Speaker for Annual Meeting of CSPA, 2018
  • Member of the Working Group on establishing Vitiligo Canada, a patient support organization in Canada (2023-present)
  • Physician supporter for patient-led initiatives for increasing skin patients’ access to medications by raising public awareness 2024-present

Editorial Board and Editor Appointments:

  • Associate Editor: Frontiers in Medicine (Dermatology), 2016 – present (Associate Editor)
  • Editorial Board Member: Journal of American Academy of Dermatology (JAAD), 2018 – present
  • Editorial Board Member: Journal of Cutaneous Medicine and Surgery (JCMS), 2004 – present
  • Editorial Board Member: World Journal of Clinical Oncology, 2010 – present
  • Editorial Board Member: Global Journal of Dermatology and Venerology, 2018- present
  • Senior Editor, Global Journal of Translational Research, 2012 – present

Reviewer for Academic Journals and Funding Agencies:

  • Invited reviewer for New England Journal of Medicine, JID, JAAD, JAMA Dermatology, JCMS and 15 other national and international
  • Invited reviewer for Canadian Dermatology Foundation, Canadian Institute of Health Research (CIHR), and 3 other international funding

Dermatology Education:

  • Serving on the Dermatology Resident Education Committee, University of British Columbia, 2001-present
  • Serving on the Undergraduate Dermatology Education Committee, University of British Columbia, 2001-present
  • Provide dermatology teaching (didactic as well as bedside teaching) to more than 4000 medical students, and more than 100 dermatology residents at University of British Columbia, 2000 – present
  • DRIVE Examiner for graduating dermatology residents in Canada, Royal College of Physicians and Surgeons of Canada, 2017, 2018
  • BoSS Lecturer for Canadian dermatology residents, Canadian Dermatology Association, 2016, 2017
  • Teaching on skin cancer diagnosis and management to GP Oncologists, Province of British Columbia, 2005-present
  • Training 50 graduate students, research fellows, and clinical fellows for Canada and other countries in investigative dermatology (2005-present) Dermatology

Volunteering Activities:

  • Co-lead, WACD COVID19 Prevention Committee, Vancouver, 2020
  • Volunteer dermatologist, British Columbia Health Fairs, 2017 – present
  • Dermatology lead, Winter Olympics Medical Services, 2010
  • Volunteer speaker on behalf of Canadian Dermatology Association on sun safety, vitiligo, hyperhidrosis and other skin diseases on TV and other media 2003 – present
  • Specialty speaker representing dermatology to medical student career orientation, Faculty of Medicine, University of British Columbia 2005-2007

Number of Publications Authored

263 (including abstracts, articles, and peer-reviewed articles)

List of Publications Authored 

PUBLICATIONS AND PATENTS & INTELLECTUAL PROPERTY RIGHTS (YOUWEN ZHOU)

Summary: –Total: 116 articles, Citations >7439, Google Scholar H index: 49; 5 patents Authorship explanations: –Underline: Trainees under my direct supervision –FSA: First author or senior author:

I (a). Publications on Vitiligo and Skin Pigmentation:

  1. Liang, , Yang, S., Zhou, Y., Cui, J., Ren, Y., Chen, J., Fan, X., Sun, L., Xiao, F., Gao, M., Fang, Q., Xu, S., Huang, W., and Zhang, X. Evidence for two susceptibility loci on Chromosome 22q12 and 6p21-p22 in Chinese generalized vitiligo families. J Invest Dermatol. 2007; 127:2552-57
  2. Zhou, Therapeutic options for common pigmentation disorders. CME Journal, 2007, Jan 64-67. FSA
  3. Ren, Y, Yang S, Xu, S , Gao M, Huang W, Gao T,Fang Q, Quan C, Zhang C, Sun L, Liang Y, Han J, Wang Z, Zhang F, Zhou Y, Liu J, Zhang Genetic Variation of Promoter Sequence Modulates XBP1 Expression and Genetic Risk for Vitiligo. PLoS Genetics. 2009; 5: e1000523 PMID: 19543371
  4. Xu, , Zhou, Y et al and Zhang, X-J. Platelet-derived growth factor receptor alpha gene mutations in vitiligo vulgaris. Acta Dermatol Venereol. 2010. 90: 131-5.
  5. Quan C, Ren YQ, Xiang LH, Sun LD, Xu AE, Gao XH, Chen HD, Pu XM, Wu RN, Liang CZ, Li JB, Gao TW, Zhang JZ, Wang XL, Wang J, Yang RY, Liang L, Yu JB, Zuo XB, Zhang SQ, Zhang SM, Chen G, Zheng XD, Li P, Zhu J, Li YW, Wei XD, Hong WS, Ye Y, Zhang Y, Wu WS, Cheng H, Dong PL, Hu DY, Li Y, Li M, Zhang X, Tang Y, Tang XF, Xu SX, He SM, Lv YM, Shen M, Jiang HQ, Wang Y, Li K, Kang XJ, Liu YQ, Sun L, Liu ZF, Xie SQ, Zhu CY, Xu Q, Gao JP, Hu WL, Ni C, Pan TM, Li Y, Yao S, He CF, Liu YS, Yu ZY, Yin XY, Zhang FY, Yang S, Zhou Y, and Zhang Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nature Genetics, 2010. 42: 614-8 FSA PMID: 20526339
  6. Zhu K, Lv YM, Yin X, Wang Z, He S, Cheng H, Hu D, Zhang Z, Li Y, Zuo X, Zhou Y, Yang S, Zhang XJ and Zhang Psoriasis regression analysis of MHC Loci identifies shared genetic variants with vitiligo. PLOS One 2011; 6:e23089 PMID: 22125590
  7. Yu R, Huang Y, Wang Y, Su M, Martinka M, Zhang S, Gao M, We S, Xu A, Zhang X and Zhou Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin. PLOS one 2012; 7: e51040 FSA PMID: 23251420
  8. Yu R, Huang Y, Zhang X, and Zhou Potential role of neurogenic inflammatory factors in the pathogenesis of vitiligo. J Cutan Med Surg 2012; FSA PMID: 22784515
  9. Tang X-F, Zhang Z, Hu D-Y, Xu A-E, Zhou H-S, Sun L-D, Gao M, Gao T-W, Gao X-H, Chen H-D, Xie H-F, Tu C-X, Hao F, Wu R-N, Zhang F-R, Liang L, Pu X-M, Zhang J-Z, Han J-W, Pan G-P, Wu J-Q, Li K, Su M-w, Du W-D, Zhang W-J, Liu J-J, Xiang L-H, Yang S, Zhou Y, and Zhang X-J. Association analyses identify three new susceptibility loci for vitiligo in the Chinese Han J Invest Dermatol. 2013:133; 403-410 FSA PMID: 20526339
  10. Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, Zhou Y, Deng A, Hunter CA, Luster AD, Harris CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo. Sci Transl Med. 2014 ; 6 (223): 223ra23 PMID: 24523323
  11. M AlJasser, V Richer, N Ball, H Lui, and Y Photolichenoid papules within vitiligo induced by narrowband UVB phototherapy Journal of the European Academy of Dermatology and Venereology 2016; 30 (8):1428-1429 FSA PMID: 26304018
  12. Q Yang, G Zhang, M Su, G Leung, H Lui, P Zhou, Y Wu, J Zhou, J Xu, X Zhang, and Y Vitiligo Skin Biomarkers Associated With Favorable Therapeutic Response. Frontiers in immunology. Front. Immunol. 2021;12:613031
  13. Yang Q, Liu L, Su MW, Zhou Vitiligo Responds to Topical AhR Agonist Tapinarof (WBI1001). JAAD Case Reports. 2023 Jul 26. doi: https://doi. org/10.1016/j. jdcr. 2023.06. 051 I

I(b). Publications on Dermatology Drug Development and Research:

  1. Zhou, Y, Dutz J, and Ho Mycophenolate mofetil for dermatological diseases. J Cut Med Surg. 2001; 5 (3 suppl): 26-29. FSA
  2. Zhou, Y, Rothenthal D, Dutz J, and Ho Mycophenolate mofetil for psoriasis: a two center, prospective, open-label clinical trial. J Cut Med Surg. 2003;7: 193-197. FSA PMID: 12704533
  3. Afifi T, De Gannes G, Huang C, Zhou Topical therapies for psoriasis: Evidence-based review. Canadian Family Physicians, 2005; 51:519-525 FSA PMID: 15856971
  4. Zhang J, Adam D, Stebbing E, Gerbrandt J, Lui H, Shapiro J, and Zhou Efficacy of a day-care program in the treatment of psoriasis. J Cut Med Surg. 2008; 12:211-216. FSA PMID: 18845089
  5. Wellman-Labadie O, Zhou The US Orphan Drug Act: Rare disease research stimulator or commercial opportunity? Health Policy. 2010; 95:216-28. FSA PMID: 20036435
  6. Zhang YH, Zhou Y, Ball N, Su MW, Xu JH, Zheng Pityriasis rubra pilaris type I: Upregulation of tumor necrosis factor alpha and response to adalimumab monotherapy. J Cut Med Surg 2010;14:185-8. FSA PMID: 20642989
  7. Bissonnette R, Chen G, Bolduc C, Maari C, Li B, Lyle M, Tang L, Wanggui Y, Webster J and Zhou Efficacy and safety of topical WBI1001 in the treatment of atopic dermatitis: results from a phase IIa randomized placebo controlled clinical trial. Arch Dermatol, 2010; 146:446-9 FSA PMID: 20404242
  8. Fumerton R, Martinka M and Zhou Refractory Cutaneous Rosai-Dorfman Disease Responsive to Cryotherapy. Cutis 2011 Jun;87(6):296-9. FSA PMID: 21838087 Bissonnette R, Yves P, Zhou Y, Tan J, Hong C-h, Webster J, Tang L, and Lyle Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week multi-centered randomized double-blind trial. Br J Dermatol 2012;166:853-860 PMID: 22182053 Kalia S, Toosi B, Bansback N, Astaneh A, Zhou Y, Shapiro J, Lui Assessing adherence with phototherapy protocols Journal of the American Academy of Dermatology 2014; 6: 1259-1261 PMID: 25454035
  9. Wang, , et al. Zhou, Y and Ma X. Novel Quinazoline Derivatives Bearing Various 4- Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines. Chemical biology & drug design, 2015. FSA PMID: 26613384
  10. Griffiths, E. Reich, K. Lebwohl, M. van de Kerkhof, P. Paul, C. Menter, A. Cameron, G. Erickson, J. Zhang, L. Secrest, R. J. Ball, S. Braun, D. K. Osuntokun, O. O. Heffernan, P. Nickoloff, B. J. Papp, K. and Uncover- investigators (et al Zhou Y et al) Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis. The Lancet 2015; 386: 541-551 PMID: 26072109
  11. Yu, , et al. Zhou Y and Ma X. Novel 4-anilinoquinazoline derivatives featuring an 1- adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines. European journal of medicinal chemistry, 2016. 110: p. 195-203. FSA PMID: 26829280
  12. Song Z, Ge Y, Wang C, Huang S, Shu X, Liu K, Zhou Y, and Ma Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M- Mediated Resistance in Non-Small-Cell Lung Cancer J. Med. Chem., 2016, 59 (14), pp 6580–6594. FSA PMID: 26882288
  13. Agrawal, , Su, M-w, Huang, Y., Hsing, M., Cherkasov, A., and Zhou, Y. Computer-Aided Discovery of Small Molecule Inhibitors of Thymocyte Selection-Associated High Mobility Group Box Protein (TOX) as Potential Therapeutics for Cutaneous T-Cell Lymphomas. Molecules, 2019. 24(19): p. 3459. FSA PMID: 31554191
  14. Van-de-Velde, and Y. Zhou, Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma. J Cutan Med Surg, 2019: p. 1203475419840629. FSA PMID: 30943788
  15. Sivanand, , Surmanowicz, P., Alhusayen, R., Hull, P., Litvinov, I., Zhou, Y., and Gniadecki, R. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. Journal of cutaneous medicine and surgery, 2019. 23(5): p. 537-544. PMID: 31353944OTHER PUBLICATIONS
  16. Wang YH, Zhang XY, Khan R, Zhou, Y, Huang L-H, Ehrlich Methylated DNA-binding protein from human placenta recognizes specific methylated sites on several prokaryotic DNAs. Nucleic Acid Res 1986; 14:9843-9860.
  17. Baricos WH, Zhou, Y, Feurst R, Barrett A, Shah The role of aspartic and cysteine proteinases in albumin degradation by rat kidney cortical lysosomes. Arch Biochem Biophysics 1987; 256:687-691.
  18. Baricos WH, Murphy G, Zhou Y, Nguyen HH, Shah Degradation of glomerular basement membrane by purified mammalian metalloproteinases. Biochemi J 1988; 254:609-612.
  19. Baricos WH, Zhou, Y, Mason RW, Barrett Human kidney cathepsons B and L: characterization and potential role in degradation of glomerular basement membrane. Biochem J 1988; 252:301-304.
  20. Baricos WH, Cortez SL, Le QC, Zhou,Y, Dicarlos RM, O’Connor SE, Shah Glomerular basement membrane degradation by endogenous cystein proteinases in isolated rat glomeruli. Kidney International 1990; 38:395-401.
  21. Rodriguez D, Zhou Y, Rodriguez JR, Durbin R, McAllister WT, Esteban Regulated expression of a nuclear gene by T3 RNA polymerase and lac repressor delivered by recombinant vaccinia viruses. J Virology 1990; 64:4851-4857.
  22. Zhou Y, Giordano T, Durbin R, McAllister Synthesis of functional messenger RNA in mammalian cells by bacteriophage T 3 RNA polymerase. Mol Cell Biol 1990; 10:4529- 4537. FSA
  23. Leung-Hagesteijn C, Spence AM, Stern BD, Zhou, Y, Su M, Hedgecock EM, Culotti Unc-5, a transmembrane protein with immunoglobulin and thrombospondin type 1 domains, guides cell and pioneer axon migrations in C. elegans. Cell 1992; 71:289-299.
  24. Hamelin M, Zhou Y, Su M, Scott I, Culotti Expression of the unc-5 guidance receptor in the touch neurons of C. elegans steers their axons dorsally. Nature 1993; 364:327- 330.
  25. MacDonald LE, Zhou Y, McAllister Termination and slippage by bacteriophage T7 RNA polymerase. J Molecular Biol 1993; 87:1030-1047.
  26. McAllister WT, Zhou, Y, MacDonald L, Raskin Regulation of transcription elongation
  27. and termination. J Cell. Biochem 1993; 147:223-275.
  28. Zhou Y, Lee H-S T, Koosheh F, Fujisawa H, Sauder DN, Kondo Effects of UVB irradiation on keratinocyte growth factor and its receptors expression in cultured human keratinocytes. Exp Dermatol 1996; 5:138-144. FSA
  29. Su M, Merz DC, Killeen MT, Zhou, Y, Zheng H, Kramer JM, Hedgecock EM, and Culotti Regulation of the UNC-5 netrin receptor initiates the first reorientation of migrating distal tip cells in Caenorhabditis elegans. Development. 2000; 127:585-594.
  30. Zhou, Y, Barnet M, Rivers Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol. 2000;136:717-721. FSA
  31. Dai D, Makretsov N, Campos E, Martinka M, Huang C, Zhou, Y, Huntsman D, and Li Increased expression of integrin linked kinase correlates with melanoma invasion. Clin. Cancer Res. 2003; 9:4409-4414.
  32. Su MW, Dorocicz I, Degawska V, Voss N, Ho V, Li G, Gascoyne R and Zhou, Aberrant expression of T-plastin in Sezary cells. Cancer Res. 2003; 63:7122-7127. FSA PMID: 14612505
  33. Huang, CZ and Zhou, Familial bullous lichen planus (FBLP): clinical characteristics
  34. and inheritance analysis. J Cut Med Surg. 2005; 9:217-222. FSA
  35. Zhou, Y, Dai D, Martinka M, Su M, Zhang Y, Campos E, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho, V, Li Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005; 124:1044-52. FSA
  36. Ringrose A, Zhou Y, Pang E, Zhou L, Lin AE-J, Sheng G, Li XJ, Weng A, Su M-W, Pittelkow MR and Jiang Evidence for an oncogenic role of AHI-1 in Sezary syndrome, a leukemic variant of human cutaneous T-cell lymphomas. Leukemia. 2006; 20:1593- 601 PMID: 16838023
  37. Xiao, , Lu, C., Zhao, L, Jia, H., Zha, Q., Yan, X., Wang, J., Zhang, Y., Zhou, Y., Xu, S., Li, S., and Lu, A. Gene expression profiles of peripheral blood CD4 positive lymphocytes in patients with active and stable rheumatoid arthritis. Chin. J. of Tradit. Chin Med. 2006;13:14-16
  38. Tang, L, Dai, D, Martinka, , Su, MW, Zhang, Y, Li, G and Zhou, Y Aberrant Expression of CTHRC1 in human cancers. Clin Cancer Res. 2006;12:3716-3722. FSA
  39. Zhang, Y, Tang T, Su, MW, Eisen, D, Zloty, D, Warshawski, L, and Zhou, Expression of endothelins and their receptors in non-melanoma skin cancers. J Cut Med Surg. 2006; 10:269-276. FSA
  40. Zhou, Hyperhidrosis, Skin Therapy Letters 2006;1: 6-7 FSA
  41. Lu, , Xiao, C., Zhao, L, Jia, H., Zha, Q., Yan, X., Wang, J., Zhang, Y., Zhou, Y., Xu, S., Li, S., and Lu. Gene expression profile of peripheral blood CD4 positive T cells in patients with rheumatoid arthritis. Chin J. Rheum. 2006;10:438-439
  42. Lu, , Xiao, C., Zhao, L, Jia, H., Zha, Q., Yan, X., Wang, J., Zhang, Y., Zhou, Y., Xu, S., Li, S., and Lu, Comparison of gene profile of peripheral CD4+ lymphocytes in rheumatoid arthritis with cold and heat syndromes. Chin. J. of Basic Med. in Tradit. Chin. Med. 2006; 12: 130-133.
  43. Xiao , Lu C, Zhao L, Jia H, Zha Q, Yan X, Wang J, Zhang Y, Zhou Y, Xu S, Li S, and Lu A. The transcriptome characteristics of peripheral blood CD4 T cells in patients with progressive or stable rheumatoid arthritis. Chin J of Info. Chin Med. 2006; 13:14-16
  44. Xiao , Zhao, L., Lu, C., H., Zha, Q., Yan, X., Wang, J., Zhang, Y., Zhou, Y., Xu, S., Li, S., and Lu. Comparison of peripheral blood CD4 T cell gene expression profiles in RF positive and RF negative rheumatoid arthritis patients. Chin. J. of Integr. Tradit. and West. Med. 2006; 26: 689-693.
  45. Zhao L, Lu , Xiao C., Zha Q., Yan X., Wang J., Zhang Y., Yang W., Zhou Y, Li S., Lu A. Gene expression profile of periphery CD4 positive in patients with early and late stage rheumatoid arthritis. Current Immunology. 2006;26;336-339
  46. Adam, D, Beleznay K, Randhawa R, Marton M, and Zhou Review of Intravascular Lymphoma with a report of treatment with allogenic peripheral blood stem cell transplant. Cutis 2008; 82:267-272. FSA
  47. Huang C, Tian J, Tao J, Liu Y, Li Y, Yang L, Zhang J, Li Y, Chen S, Lin N, Shen G, Tu Y, and Zhou Y Endothelin signaling axis activates osteopontin expression through PI3 kinase pathway in A375 melanoma J Dermatol Sci. 2008;52:130-134. FSA
  48. Tang, L, Su, MW, Zhang, Y, Ip, W, Martinka, M, Huang C and Zhou, Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival. J Cut Med Surg. 2008; 12:64-7. FSA
  49. Tao J, Huang C, Yu N, Wu , Liu Y, Li Y, Tian J, Yang L, Zhang J, Li J, Zhou, Y and Tu Y. Olmsted syndrome: a case report and review of literature. Int J Dermatol. 2008; 47:432- 437 FSA
  50. Kennah E, Ringrose A, Zhou LL, Esmailzadeh S, Qian H, Su M-w, Zhou Y, and Jiang X Identification of tyrosine kinase, HCK, and tumor suppressor, BIN1, as potential mediators of AHI-1 oncogene in primary and transformed CTCL cells, Blood, 2009; 113:4646-55. PMID: 19211505
  51. Wang, Y, Jiang, H, Dai, D, Li, G, et al and Zhou, Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell Mel Res 2010; 23:575-8. FSA
  52. Wei S, Zhang T, Zhou Y, Zhang B, Zhu H, Li J, Huang Z, Deng L and Zhang X-J Fine Mapping of the Disseminated Superficial Porokeratosis Locus to a 7Mb Region on 18p11.3 Clin Exp Dermatol. 2010. 35: 664-7
  53. Zhou Y, Barsh G, Meyskens F, et XVIth Annual Meeting of Pan American Society for Pigment Cell Research Vancouver Pigmentation and Melanoma Research Conference ‘‘The latest developments in the research and. Pigment Cell Melanoma Res. 2010;23:695-721. FSA
  54. Ip, W, Wellman-Labadie, O, Tang, L, Su, M, Huang, Y, Dutz, J, Wang, Y, Zhang, X, and Zhou, Collagen Triple Helix Repeat Containing 1 promotes melanoma cell adhesion and survival. J Cutan Med Surg 2011 Mar-Apr;15(2):103-10 FSA
  55. Jiang M, Xiao C, Chen G, Lu C, Zha Q, Yan X, Kong W, Xu S, Ju D, Xu P, Zhou Y, Lu A Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis Front 2011;5:219-28
  56. Liu Y, Lv Y, Yang X, Ren Y, Zhang X, Guo B, Li M, Gao M, Zuo X, Zhou F, Chen G, Yin X, Sun L, Zheng X, Zhang S, Liu J, Zhou Y, Jiang T, Zhang Q, Zhang P, Li Y, Wang J, Wang J, Yang H, Yang S, Li R, and Zhang, Exome sequencing identifies NCSTN mutations in inversa acne (hidradenitis suppurativa) J Invest Dermatol. 2011 Jul;131(7):1570-2
  57. Wang, Y, Su Mw, Zhou, LL, Tu, P Zhang, XJ, Jiang, X and Zhou, Deficiency of SATB1 expression in Sézary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood 2011 Apr 7;117(14):3826-35 FSA PMID: 21270445
  58. Chen G, Lv C, Zha Q, Xiao C, Xu S, Ju D, Zhou Y, Jia W, and Lv A network-based analysis of traditional Chinese medicine cold and hot patterns in rheumatoid arthritis. Complement Ther Med 2011;20:23-30
  59. Litvinov I, Zhou Y, Kupper T, and Sasseville Loss of BCL7A expression correlates with poor prognosis in patients with early stage cutaneous T-cell lymphoma. Leukemia & Lymphoma. 2012; 54(3):653-4. PMID: 22856870
  60. Zhang Y, Wang Y, Yu R, Huang R, Su M, Dutz J, Martinka M, Xiao C, Zhang X, Zheng Z, and Zhou Molecular markers of early stage mycosis fungoides. J Invest Dermatol. 2012 (March 1 2012, online publication) FSA PMID: 22377759
  61. Mclean DI, Philips N, Zhou Y, Gallager R, and Lee 40-year Trends in Skin Cancer in British Columbia, Canada, 1973 to 2003. J Cutan Med Surg 2012; 16:83-91.
  62. Zhang, S-Q, Jiang, T, Li M, Zhang X, Ren Y-Q, Wei S-C, Sun L-D, Chen, H, Li Y, Yin X-Y, Hu Z-M, Wang Z-Y, Liu Y, Guo B-R, Tang H-Y, Tang X-F, Ding Y-T, Wang J-B, Li P, Wu B-Y, Wang W, Qian F-F, Zhou F-S, Chen G, Zuo X-B, Zheng X-D, Sheng Y-J, Gao J-P, Liang B, Li Pan, Zhu J, Xiao F-L, Wang P-G, Cui Y, Li H, Liu S-X, Gao M, Fan X, Shen S-K, Zeng M, Sun G- Q, Xu Y, Hu J-C, He T-T, Li, Y-R, Yang H-M, Wang J, Yu Z-Y, Zhang H-F, Hu X, Yang K, Wang J, Zhao S-X, Zhou Y, Liu J-J, Du W-D, Zhang L, Xia K, Yang S, Wang J, and Zhang X-J. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis Nature Genetics 2012; 44:1156-1160
  63. Aljasser M, Lui H, Zeng H & Zhou Y Dermoscopy and near-infrared fluorescence imaging of cutaneous larva Photodermatol Photoimmunol Photomed 2013: 29; 337-338 FSA
  64. Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, Woetmann A, Zhou Y, Sasseville D, Odum N Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma Blood. 2013:122 ; 943-950 (FSA) PMID: 23801634
  65. An, XJ, Li YQ, Qu XY, Zhang J, Zhang LY, Wang Zhu L, Chen SY, Zhen HX, T YT, Zhou Y, and Huang CZ. Silencing endothelin-3 expression attenuates the malignant behaviors of human melanoma cells by regulating SPARC levels. J. Huazhong Univ Sci Tech. 2013; 33:581-586 FSA
  66. Huang Y, Litvinov IV, Wang Y, Su MW, Jiang X, Kupper TS, Sasseville D, and Zhou Y Thymocyte selection-associated high mobility group box gene (TOX) is aberrantly over- expressed in mycosis fungoides and correlates with poor Oncotarget, 2014 :5 (12), 4418-4425 FSA PMID: 24947046
  67. Litvinov IV, Cordeiro B, Fredholm S, Ødum N, Zargham H, Huang Y, Zhou Y, Pehr K, Kupper TS, Woetmann A, Sasseville Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines Cell Cycle 2014; 13: 2975- 2982 PMID: 25486484
  68. Litvinov IV, Huang Y, Zhou Y, Kupper D, Sasseville Ectopic expression of cancer testis antigens in Cutaneous T-Cell Lymphoma (CTCL) patients. Clinical Cancer Research 2014;20(14):3799-808 PMID: 24850846
  69. Litvinov IV, Netchiporouk E, Cordeiro B, Zargham H, Pehr K, Gilbert M, Zhou Y, Moreau L, Woetmann A, Ødum N, Kupper TS, Sasseville Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma OncoImmunology 2014; 3 (11), e970025 PMID: 25941598
  70. Wang Y, Gu X, Zhang G, Wang L, Wang T, Zhao Y, Zhang X, Zhou Y, Kadin M, and Tu SATB1 overexpression promotes malignant T-cell proliferation in cutaneous CD30+ lymphoproliferative disease by repressing p21. Blood. 2014; 123: 3452 – 61. MID: 24747435
  71. Willerslev-Olsen A, , Litvinov IV, Fredholm SM, Petersen DL, Sibbesen NA, Gniadecki R, Zhang Q, Bonefeld CM, Wasik MA, Geisler C, Zhou Y, Woetmann A, Sasseville D, Krejsgaard T, and Ødum N IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF) Cell Cycle 2014;13:1306-1312 PMID: 24621498
  72. Wu XS, Shulte BC, Zhou Y, Haribha D, Mackinon AC, Plaza JA, Williams CB, and Hwang Depletion of M2-like tumor-associated macrophages delays cutaneous T cell lymphoma development in vivo. Journal of Investigative Dermatology. 2014; 134: 2814- 2822 PMID: 24780929
  73. Bagdonaite I, Wandall HH, Litvinov IV, Nastasi C, Becker JC, Dabelsteen S, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, Zhou Y, Sasseville D, Ødum N, Woetmann Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients Oncotarget. 2015; 6:14374-84 PMID: 25957418
  74. Cheng Y, Lu J, Chen G, Ardekani GS, Rotte A, Martinka M, Xu X, McElwee KJ, Zhang G, Zhou Stage-specific prognostic biomarkers in melanoma Oncotarget 2015; 6:4180- 4189 FSA
  75. Esmailzadeh S, Huang Y, Su MW, Zhou Y, Jiang X BIN1 tumor suppressor regulates Fas/Fas ligand–mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma 2015; 29: 1402-1413 FSA
  76. Huang Y, Su MW, Jiang X, Zhou Evidence of an oncogenic role of aberrant TOX activation in cutaneous T-cell lymphoma Blood 2015; 125 : 1435-1443 FSA
  77. Litvinov IV, Netchiporouk E, Cordeiro B, Doré MA, Moreau L, Pehr K, Gilbert M, Zhou Y, Sasseville D, Kupper The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL) Clinical Cancer Research 2015;21:2820-2829
  78. Mai, , et al. Zhou Y, and Zhang G. Therapeutic efficacy of combined BRAF and MEK inhibition in metastatic melanoma: a comprehensive network meta-analysis of randomized controlled trials. Oncotarget, 2015. 6(29): p. 28502. FSA
  79. Rotte A, Bhandaru M, Zhou Y, McElwee Immunotherapy of melanoma: Present options and future promises. Cancer and Metastasis Reviews 2015; 34: 115-128
  80. Sanusi T, Li Y, Sun L, Wang C, Zhou Y, Huang Eccrine Angiomatous Hamartoma: A Clinicopathological Study of 26 Cases. Dermatology. 2015; 231:63-9. FSA
  81. Zhang G, Cheng Y, Chen G, Tang Y, Ardekani G, Rotte A, Martinka M, McElwee K, Xu X, Wang Q, and Zhou Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. Oncotarget 2015; 6: 23026-35 FSA
  82. Liu, Y, Bahar R, Huang Y, et , and Zhou Y. Hyperhidrosis Prevalence and Demographical Characteristics in Dermatology Outpatients in Shanghai and Vancouver. PloS one, 2016. 11(4): p. e0153719. FSA
  83. Zhao H, Wang J, Kong X, Li E, Liu Y, Du X, Kang Z, Tang Y, Kuang Y, Yang Z, Zhou Y, and Wang CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer. Scientific Reports 2016; 6 (29719): 1-11 FSA
  84. Khosravi S, Martinka M, Zhou Y, Ong Prognostic significance of the expression of nuclear eukaryotic translation initiation factor 5A2 in human melanoma. Oncol Lett. 2016; 12: 3089 -3100
  1. Bahar R, Liu R, Huang R, Su M, Kalia, S, Philips, A, Zhang X, Zhou P, and Zhou Prevalence of anxiety and depression in patients with or without primary hyperhidrosis. J American Academy of Dermatology, 2016 (in press) FSA
  2. Tan, Qi, Q. Lu, C. Niu, X. Bai, Y. Jiang, C. Wang, Y. Zhou, Y. Lu, A. Xiao, C. Cytokine Imbalance as a Common Mechanism in Both Psoriasis and Rheumatoid Arthritis. Mediators Inflamm, 2017. 2017: p. 2405291.
  3. Qiu, Huang, J. Shu, X. Fan, H. Zhou, Y. Xiao, C. Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Sci Rep, 2017. 7: p. 44015. FSA
  4. Qiu, Huang, J. Lin, Y. Shu, X. Fan, H. Tu, Z. Zhou, Y. Xiao, C. Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis. Medicine (Baltimore), 2017. 96(11): p. e6337. FSA
  5. Lauenborg, Litvinov, I. V. Zhou, Y. Willerslev-Olsen, A. Bonefeld, C. M. Nastasi, C. Fredholm, S. Lindahl, L. M. Sasseville, D. Geisler, C. Wasik, M. M. Krejsgaard, T. Gjerdrum, L. M. R. Iversen, L. Odum, N. Woetmann, A. Malignant T cells activate endothelial cells via IL-17 F. Blood Cancer J, 2017. 7(7): p. e586. PMID: 28731459
  6. Wu, Hsu, D. K. Wang, K. H. Huang, Y. Mendoza, L. Zhou, Y. Hwang, S. T. IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model. Leuk Lymphoma, 2018: p. 1-9. PMID: 30277131
  7. Chen, Liu, X. Deng, B. Martinka, M. Zhou, Y. Lan, X. Cheng, Y. Cytoplasmic Pin1 expression is increased in human cutaneous melanoma and predicts poor prognosis. Sci Rep, 2018. 8(1): p. 16867.
  8. Mai, Zhou, S. Zhou, S. Zhong, W. Hong, L. Wang, Y. Lu, S. Pan, J. Huang, Y. Su, M. Crawford, R. Zhou, Y. Zhang, G. Transcriptome analyses reveal FOXA1 dysregulation in mammary and extramammary Paget’s disease. Hum Pathol, 2018. 77: p. 152-158. FSA
  9. Wong, T.Y., Y. Huang, and Y. Zhou, Drug eruption to rosuvastatin with recurrence on simvastatin: a case report. J Cutan Med Surg, 2018. 22(3): p. 359-361. FSA
  10. Zhao, J. Chen, S. Y. Qu, X. Y. Abdul-Fattah, B. Lai, T. Xie, M. Wu, S. D. Zhou, Y. Huang, C. Z. Increased Cthrc1 Activates Normal Fibroblasts and Suppresses Keloid Fibroblasts by Inhibiting TGF-beta/Smad Signal Pathway and Modulating YAP Subcellular Location. Curr Med Sci, 2018. 38(5): p. 894-902. FSA
  11. Ghazawi, M. Lefrancois, P. Xie, P. Rajakulendran, T. Copley, M. Drucker, A. M. Alavi,
  12. Zhou, Y. Litvinov, I. V. A Vision for an Academic Career Mentorship Program for Canadian Dermatology Residents. J Cutan Med Surg, 2019. 23(1): p. 123-124.
  13. Khosravi-Hafshejani, , Y. Zhou, and J.P. Dutz, Acrodermatitis Continua of Hallopeau with Psoriatic Arthritis. J Rheumatol, 2019. 46(4): p. 437-438.
  14. Zhang, Zhou, S. Zhong, W. Hong, L. Wang, Y. Lu, S. Pan, J. Huang, Y. Su, M. Crawford, R. Zhou, Y. Mai, R. Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget’s Diseases. J Invest Dermatol, 2019. 139(4): p. 789-795. FSA
  15. Zhang, Lee, T. K. Lui, H. Kunimoto, B. Han, C. Zhou, Y. Kalia, S. Algorithms for ascertaining keratinocyte carcinomas using health insurance claims and prescription records. J Eur Acad Dermatol Venereol, 2019; 33(8):e275-e276).
  16. Chafe McDonald P, Saberi S, Nemirovsky O, Venkateswaran G, Burugu S, Gao D, Gillespie J, Bashashati A, Zhou Y, Shah S, Kyle A, Baker J, Delaidelli D, Andrew Minchinton A and Dedhar S. Targeting hypoxia-induced Carbonic Anhydrase IX augments immune checkpoint blockade locally and systemically. Cancer Immunology Research. 2019;7(7):1064-1078.
  17. X Zhang, MW Su, Y Cheng, M Martinka, G Wang, Y Huang, L Li, Y Immunohistochemistry analysis reveals lysyl oxidase-like 3 as a novel prognostic marker for primary melanoma. Melanoma Research 2021; 31 (2), 173-177
  18. N Kibbi, JL Owen, B Worley, JX Wang, V Harikumar, MB Downing, ..Y . et al. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology. 2022;8:618-628
  19. Aaron M. Drucker, Omer Kleiner, Rachael Manion, Anie Philip, Jan Dutz, Kathleen Barnard, Julie Fradette, Lucie Germain, Robert Gniadecki, Ivan Litvinov, Morris Manolson, P. Régine Mydlarski, Vincent Piguet, Debbie Ward, Youwen Zhou, An-Wen Chan, and the Skin Investigation Network of Canada Priority Setting Collaborative- 15View all authors and affiliations. Top Ten Research Priorities for Psoriasis, Atopic Dermatitis and Hidradenitis Suppurativa: The SkIN Canada Priority Setting Initiative。 Journal of Cutaneous Medicine and Surgery， 2023. Volume 27, Issue 2, Pages 133- 139，https://doi.org/10.1177/12034754231156103
  20. Marleine Azar, Francois Lagacé, Anastasiya Muntyanu, Elena Netchiporouk, Youwen
  21. Zhou, Charles Lynde, Linda Moreau, Steve Mathieu, Denis Sasseville, Rachel Asiniwasis, Neil H Shear, Robert Gniadecki, Elham Rahme, Ivan V Litvinov. Measuring h-index and scholarly productivity in academic dermatology in Canada.
  22. Scientometrics Volume 128 Issue 2 Pages 1071-1090

III. PATENTS:

  1. Novel biomarkers of T cell malignancies and uses Inventors: Zhou, Y, Huang, Y, Wang Y, and Su M. Patent number: US20140308241 (2012) It is challenging to diagnose mycosis fungoides (MF), the main form of cutaneous T cell lymphoma. The difficulty is due to the clinical and histological resemblance of MF to the far more common skin inflammatory diseases, such as chronic dermatitis and psoriasis, and the fact that there are no specific positive identification markers for the malignant cells. By systematically characterizing the transcriptome difference between establish MF and benign inflammatory dermatoses, our lab had uncovered 19 genes that allow sensitive and specific separation between MF and its benign counterparts. Based on these findings, which are summarized in this article, the first specific and sensitive histological test for CTCL, named “SeeTCL” had been developed. A patent application had been filed, and CIHR recently awarded a POPI grant to support further research to develop this technology. This study, together with the SeeTCL test, may influence how MF is diagnosed and managed in the future.
  2. TOX inhibition for the treatment of Inventors: Zhou Y, Huang Y, Wang Y, Su M, and Jiang X. US Patent 20,160,002,626 (2016) TOX is an essential T cell developmental factor. However, upon maturation, the T cells normally do not express this molecule. Therefore it is highly abnormal that malignant T cells express this molecule at abundant amounts. Preliminary experiments in vitro showed selective inhibition of this molecule lead to dramatic reduction of the survival of malignant cells. This invention describes methods and process of using TOX inhibition as a treatment of cancers that are dependent upon aberrant TOX activation, including cutaneous T cell lymphoma.
  3. 3,5-Dihydroxy-4-isopropylsteilbene (DHIS) as mitocidal agent and its therapeutic uses Inventors: Zhou, Y , Mingwan Su, Yang Wang, Yuanshen Huang, Xiao US Patent App. 15/045,063 (2018) This invention is based on our discovery that DHIS has previously unknown and unexpected anti-demodex mite properties. Therefore, DHIS has therapeutic potential for treating skin conditions caused or exacerbated by the colonization or overgrowth of demodex mites, such as rosacea and other acneiform disorders.
  4. Substituted hydroxystilbenes as AhR and Nrf2 modulators and their therapeutic applications Inventors: L Tang, MPA Lyle, Y Zhou US Patent 11,000,485 (2021)
  5. Specialized pro-resolving mediators (SPMs) as melanocyte growth factor and pro- survival factors and uses Inventor; Y Zhou et al. International patent application PCT/CA2022/050415 (2022)
Dr. Geneviève Gavigan – Regional Director, Ontario (Election)

Dr. Gavigan

 

Present Affiliations

Academic

  • The University of Ottawa

Clinical

  • The Ottawa Hospital
  • The Children’s Hospital of Eastern Ontario

CDA Involvement 

  • CDA member

Other National, Provincial and Local Dermatology Societies

  • Secretary for National Capital Society, Ottawa, ON, 4 years
  • DRIVE (Dermatology Residents Innovation & Vision in Education) Co-Chair for 2024- 2025 andPlanning Committee member for 2023-2026.

Medical Society, Governmental and/or Professional Appointments, Awards and Honours

  • Clinical Teaching Award, awarded by Dermatology residents; presented at the Canadian Dermatology Association 99th Annual Conference, Ottawa 2024

Number Of Publications Authored

  • 20 peer reviewed articles

List of Publications Authored

  1. Aw K, and Gavigan G. Treatment of discoid lupus erythematosus scarring alopecia with deucravacitinib: a case report. Accepted to JCMS.
  2. Waugh M, and Gavigan G. Drug Induced Subacute Cutaneous Lupus Erythematosus Secondary toDupilumab: A Case Report. Accepted to JCMS. May 2024.
  3. DeBiasio C, Nizalik E, Gavigan A Sclerotic Plaque on the Face. Accepted to CMAJ Practice-Clinical Images. Feb 2025.
  4. Martinez-Cabriales S, Marcoux D, Liy-Wong C, Prajapati VH, Sibbald C, Cunningham N, Lansang P, Tonkin R, Joseph M, Wong L, Spring S, Gavigan G, Ramien M. Multicenter Canadian case series of pediatric patients less than 12 years of age with moderate-to- severe atopic dermatitis treated with Pediatr Dermatol. 2023 Oct 31. doi: 10.1111/pde.15418. Epub ahead of print. PMID: 37906120.
  5. Cino D, Gavigan G. Successful treatment of exfoliative cheilitis with dupilumab: A case report. SAGEOpen Med Case Rep. 2023 Aug 7;11:2050313X231193076. doi: 10.1177/2050313X231193076. PMID: 37560382; PMCID: PMC10408346.
  6. Seale E, Gavigan G. Exacerbation of human papillomavirus infection with initiation of upadacitinib for atopic dermatitis. JAAD Case Rep. 2023 May 3;36:60-62. doi: 10.1016/j.jdcr.2023.04.019. PMID: 37250011; PMCID: PMC10220210.
  7. Aw M, Gresham L, Spurr A, Gavigan G. Reactive infectious mucocutaneous eruption following COVID-19infection in vaccinated JAAD Case Reports 2023 Jan;31:35-
  8. doi: 10.1016/j.jdcr.2022.10.018.
  9. Alison S, DeBiasio C, El Demellawy D, Gavigan G. An unusual case of pediatric embryonal rhabdomyosarcoma with subsequent diagnosis of neurofibromatosis type 1. Peds Derm. May 2022.https://doi.org/10.1111/pde.15009.
  10. Ghazawi FM, Cheung K, Gavigan G. Rapidly enlarging scalp nodule in a 20 month old child. CMAJ. 2020 Sep 14;192(37):E1066.
  11. Colantonio S. Hedin E, Oi-Yee Li H, Gavigan G. Management of congenital cutaneous candidiasis in a healthy term baby: A case report. Available online Sep 2019.
  12. Gavigan G, Kanigsberg N, Ramien M. Pediatric Stevens-Johnson Syndrome/Toxic Epidermal NecrolysisHalted by J Cutan Med Surg. Available online Feb 2018.
  13. Gavigan G, McEvoy A, Walker J. Patterns of Skin Disease in a Canadian prison population: a retrospective study. CMAJ Open. 2016 Apr-Jun; 4(2): E326–E330.
  14. Gavigan G, McEvoy A, Beecker J. Contact cryoprobe sterilization practices: a patient quality and safety issue for dermatologists. J Cutan Med Surg. 2015 Jul-Aug;19(4):388-
  15. Gavigan G, Beecker J. Reactive hemophagocytic syndrome in a patient with adult-onset Still disease. J Am Acad Dermatol 2014;71(3):e77-8.
  16. Gavigan G, McEvoy A, Young V. Acute rhabdomyolysis as a complication of interferon treatment for stage IIIc melanoma. J Cutan Med Surg 2014;18(4):277-9.
  17. Gavigan G, Yang WY, Santucci S, Harrison R, Karsh J. The prophylactic use of C1 inhibitor in hereditary angioedema patients undergoing invasive surgical procedures: a retrospective study. Allergy Asthma Clin Immunol 2014;10(1):17.
  18. Doumit J, Gavigan G, Pratt Allergic contact dermatitis from dimethyl fumarate after contact with Chinese sofa. J Cutan Med Surg 2012;16(5):353-6.
  19. LaBerge L, Pratt M, Fong B, Gavigan G. A 10-year review of p-phenylenediamine allergy and related para-amino compounds at the Ottawa patch test clinic. Dermatitis 2011;22(6):332-4.
  20. Csaszar E, Gavigan G, Ungrin M, Thérien C, Dubé P, Féthière J, Sauvageau G, Roy, DC, Zandstra Anautomated system for delivery of unstable protein to hematopoietic stem cell cultures. Biotechnol Bioeng 2009;103(2):402-12.
  21. Gavigan, G. (2007). “Integrating controlled delivery of TAT-HOXB4 into a closed-system human blood stem cell expansion bioprocess.” Institute of Biomaterials and Biomedical Engineering. Toronto, University of Toronto. Master of Applied Science: 110.
Dr. Maxwell Sauder – Regional Director, Ontario (Election)

 

Dr Sauder

 

Present Affiliations

Academic

Assistant Professor, University of Toronto

Clinical

Onco-dermatologist, Princess Margaret Cancer Centre Research Director, Toronto Research Centre Director,Pigmented Lesion Clinic, Toronto Dermatology Centre

CDA Involvement

  • Treasurer (June 2023-June 2025)
  • Member, Sun Awareness Working Group (2017-2022)
  • Resident Representative, CDA Annual Meeting Organizing Committee (2012-2015)

Other National, Provincial and Local Dermatology Societies

  • Secretary, Dermatology Association of Ontario (2021-Present)
  • Member at Large, Section of Dermatology, Ontario Medical Association (2025- Present)
  • Treasurer, Section of Dermatology, Ontario Medical Association (2020-2024)

Number of Publications Authored

51

List of Publications Authored

  1. Genta S, Araujo DV, Hueniken K, Pipinikas C, Ventura R, Rojas P, Jones G, Butler MO, Saibil SD, Yu C,Easson A, Covelli A, Sauder MB, Fournier C, Saeed Kamil Z, Rogalla P, Arteaga DP, Vornicova O, Spiliopoulou P,Muniz TP, Siu LL, Spreafico A. Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open 2024 Nov 15; 9(11): 103978. [Epub ahead of print] PMID: 39549683 /doi: 10.1016/j.esmoop.2024.103978
  2. 2. Apalla Z, Freites-Martinez A, Grafanaki K, Ortiz-Brugues A, Nikolaou V,Fattore D, Sollena P, Deverapalli S, Babakoohi S, Galimont A, Kluger N, Beylot-Barry M, Larocca C, Iriarte C,Smith J, Tattersall I, Dodiuk-Gad R, Sauder M, Carrera C, Kwong B, Whitley M, Leboeuf N, Romano P, StaraceM, Mateeva V, Riganti J, Hirner J, Patel AB, Reyes-Habito CM, Kraehenbuehl L, Kheterpal M, Fida M, Hassel J, Lacouture M, Sibaud V.Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paperbased on the first Europe/USA Delphi consensus process. J Eur Acad Dermatol Venereol 2024 Oct 26; 00: 1–12. https://doi.org/10.1111/jdv.20391
  3. Yadav G, Miller-Monthrope Y, Rao J, Adam DN, Asiniwasis RN, Grewal P, Han C, Joseph M, Langley RG, LyndeCW, Metelitsa A, Mitsos L, Ogunyemi B, Purdy KS, Sauder M, Yeung J, Optimizing the management ofpsoriasis in patients with skin of colour: a canadian delphi consensus, JAAD International 2024 Sep 28, doi:doi.org/10.1016/j.jdin.2024.09.015.
  4. Bissonnette R, Warren RB, Pinter A, Agner T, Gooderham M, Schuttelaar MLA, Crépy MN, Stingeni L, Serra-Baldrich E, Baranowski K, Korn S, Kurvits M, Plohberger U, Strange Vest N, Schliemann S; trial investigators.Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials. Lancet. 2024 Aug3; 404(10451): 461-Epub 2024 Jul 18. PMID: 39033766 / doi: 10.1016/S0140-6736(24)01027-4
  5. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA, Stein Gold L, Bouaziz JD, Pink AE,Carrascosa JM, Rewerska B, Szepietowski JC, Krasowska D, Havlíčková B, Kalowska M, Magnolo N, Pauser S,Nami N, Sauder MB, Jain V, Padlewska K, Cheong SY, Fleuranceau Morel P, Ulianov L, Piketty C; ARCADIA 1and ARCADIA 2 Study Investigators. Nemolizumab with concomitant topical therapy in adolescents andadults with moderate- to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024 Aug 3; 404(10451): 445-Epub 2024 Jul 24. PMID: 39067461 / doi: 10.1016/S0140-6736(24)01203-0.
  6. Girnita A, Fournier C, Bjerring P, Kauppi S, Andriessen A, Lynde C, Sauder M, Stensvold A. INDIVIDUAL ARTICLE:NECOM 4: Algorithm Integrating Skincare for the Management of Immunotherapy-Related CutaneousAdverse Events for Cancer Patients and Survivors. J Drugs Dermatol. 2024 Aug 1; 23(8): 85411s3-85411s10. PMID: 39093665 / doi:10.36849/JDD.85411
  7. Chen ST, Semenov YR, Alloo A, Bach DQ, Betof Warner A, Bougrine A, Burton L,Cappelli LC, Castells M, Cohen J, Dewan AK, Fadden R, Guggina L, Hegde A, Huang V, Johnson DB,Kaffenberger B, Kroshinsky D, Kwatra S, Kwong B, Lacouture ME, Larocca C, Leventhal J, Markova A, McDunnJ, Mooradian MJ, Naidoo J, Choi J, Nambudiri V, Nelson CA, Patel AB, Pimkina J, Rine J, Rubin KM, Sauder M,Shaigany S, Shariff A, Sullivan RJ, Zubiri L, Reynolds KL, LeBoeuf NR. Defining D-irAEs: consensus-baseddisease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitortherapy. J Immunother Cancer 2024 Apr 10; 12(4): e007675. PMID: 38599660 / doi: 10.1136/jitc-2023-007675
  8. Girnita A, Bjerring P, Kauppi S, Lynde CW, Sauder MB, Andriessen A. INDIVIDUAL ARTICLE: NECOM 3: APractical Algorithm for the Management of Radiation Therapy-Related Acute Radiation Dermatitis. J DrugsDermatol 2023 Nov 1; 22(11):SF400354s3-SF400354s10. PMID: 37943258 / doi: 10.36849/JDD.SF400354
  9. Genta S, Lajkosz K, Yee NR, Spiliopoulou P, Heirali A, Hansen AR, Siu LL, Saibil S, Stayner LA, Yanekina M,Sauder MB, Keshavarzi S, Salawu A, Vornicova O, Butler MO, Bedard PL, Razak ARA, Rottapel R, ChruscinskiA, Coburn B, Spreafico A. Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with ImmuneCheckpoint InhibiTors (ALERT). J Exp Clin Cancer Res 2023 Oct 21; 42(1): 276. PMID: 37865776; PMCID:PMC10589949 / doi:10.1186/s13046-023-02851-6
  10. Fournier C, Hirsch I, Spreafico A, Butler MO, Dhani N, Sauder MB.Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpointinhibitors: A case series and review of the literature. SAGE Open Med Case Rep 2023 Aug 25;11:2050313X231195462 PMID: 37654554; PMCID:PMC10467211 / doi: 10.1177/2050313X231195462
  11. Kwatra S, Yosipovitch G, Legat FJ, Reich A, Paul C,Simon D, Naldi L, Lynde C, De Bruin- Weller MS, Nahm WK, Sauder M, Gharib R, Barbarot S, Szepietowski JC,Conrad C, Fleischer A, Laquer VT, Misery L, Serra- Baldrich E, Lapeere H, Ahmad F, Jabbar Lopez ZK, Piketty C,Ständer S; OLYMPIA 2 Investigators. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl JMed 2023 Oct 26; 389(17): 1579-1589. PMID: 37888917 / doi: 10.1056/NEJMoa2301333
  12. Fournier C, Sauder MB, Andriessen A, Butler M, Claveau J, Jijal T, Lynde CW. Casmo prevention andmanagement of four common cutaneous toxicities associated with targeted cancer therapies:papulopustular eruption, xerosis, paronychia, and hand-foot skin reaction. Skin Therapy Lett. 2023 AugSuppl; 28(4)
  13. Fournier C, Sauder MB, Kamil ZS, Butler MO. Kaposi sarcoma in a patient treated withupadacitinib for rheumatoid arthritis. JAAD Case Reports 2023 Sep; 39: 145-149. PMID: 37693927; PMCID: PMC10491778 / doi: 10.1016/j.jdcr.2023.07.019
  14. Fournier C, Butler MO, Sauder MB. The use of interleukin-23 inhibitors to treat immune-related psoriasis induced by immune checkpoint inhibitors and in patients withactive cancer: A case series and review of the literature. SAGE Open Med Case Rep. 2023 Jun16;11:2050313X231181035. PMID: 37342421; PMCID: PMC10278391 / doi: 10.1177/2050313X231181035
  15. 15.Mital R, Otto TS, Savu A, Baumrin E, Cardones AR, Carlesimo M, Caro G, Freites-Martinez A, Hirner JP, Markova A, McLellan BN,Rossi A, Sauder MB, Seminario-Vidal L, Sibaud V, Owen DH, Dulmage BO, Chen ST, Kaffenberger BH.Detection of novel therapies using a multi- national, multi-institutional registry of cutaneous immune-relatedadverse events and management. Int J Dermatol. 2023 Aug;62(8):1020-1025. Epub 2023 May 19. PMID: 37203799 / doi: 10.1111/ijd.16714
  16. Fournier C, Sauder MB. Reader Comment Regarding “Survey ofOncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by EpidermalGrowth Factor Receptor Inhibitors”. J Cutan Med Surg 2023 Mar 16: 12034754231163790. [Epub ahead ofprint]. PMID: 36927192 / doi: 10.1177/12034754231163790
  17. Girnita A, Bjerring P, Kauppi S, Lynde C, SauderM, Andriessen A. Supplement Individual Article: NECOM Skincare Algorithm for Patients With Cancer andSurvivors. J Drugs Dermatol 2023 Jan 1; 22(1): 3595573-359557310. PMID:
  18. 18. Loo WJ, Turchin I, Prajapati VH, Gooderham MJ, Grewal P, Hong CH, Sauder M, Vender RB,Maari C, Papp KA. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis onthe TYK2 Pathway. J Cutan Med Surg 2023 Jan-Feb; 27(1_suppl): 3S-24S. Epub 2022 Dec 15. PMID:36519621 / doi:10.1177/12034754221141680
  19. Sauder MB. Cutaneous squamous cell carcinoma: risk stratification andstaging. Canadian Dermatology Today 2022 May; 3(2): 8-11
  20. Fournier C, Sauder MB. Reader CommentRegarding “Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review”. JCutan Med Surg 2023 Jan-Feb; 27(1):77. Epub 2022 Oct 31. PMID: 36314640 / doi:10.1177/12034754221134228
  21. Sauder M. Systemic treatments for non-melanoma skin cancers. Canadian Dermatology Today 2022 Dec;3(4): 8-12.
  22. Claveau J, Sauder MB, Andriessen A, Butler M, Lynde CW, Hijal T. Casmo Algorithm forManagement of Hormonal Therapy-Related Cutaneous Adverse Effects in Oncology Patients. Skin TherapyLett 2022 Nov Suppl
  23. Sauder MB¸Claveau J, Butler M, Andriessen A, Hijal T, Lynde CW. CaSMOManagement of Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: A Practical Primer. SkinTherapy Lett 2022 Sep Suppl
  24. Said JT, Singer S, Iannattone L, Sauder M, LeBoeuf NR. Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor-Induced Hand- Foot Skin Reaction. JAMA Dermatol2022 Jul 1; 158(7): 824-826. PMID: 35544124 / doi: 10.1001/jamadermatol.2022.1425
  25. Sauder MB. Itchingfor Relief: The Evidence of Fixed Dose Calcipotriol Plus Betamethasone Diproprionate Foam for Psoriasis.Canadian Dermatology Today Winter 2022 Special Supplement; 3-9
  26. Sauder M, Butler M. Reader Comment Regarding “Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: ADermatology Perspective on Management”. J Cutan Med Surg 2022 Jan-Feb; 26(1):105. Epub 2021 Sep 20.PMID: 3454308 / doi:10.1177/12034754211041610
  27. Girnita A, Lorentzen H, Kauppi S, Lynde C, Sauder M, Schmidt H, Andriessen A, Stensvold Supplement individual article: Skincare for Cancer Patients in Scandinavia. J Drugs Dermatol 2021 Dec 1;20(12): ss4-s14. PMID: 34898158 / doi: 10.36849/jdd.M1221
  28. Hijal T, Sauder MB, Andriessen A, Claveau J, Lynde Canadian Skin Management in Oncology Group(Casmo) Algorithm for the Prevention and Management of Acute Radiation Dermatitis. Skin Therapy Lett 2021Nov 1
  29. Lacouture ME, Choi J, Ho A, Leventhal J, McLellan BN, Andriessen A, Sauder MB, Mitchell E. USCutaneous Oncodermatology Management (USCOM): A Practical Algorithm. J Drugs Dermatol 2021 Sep 1;20(9): 3ss-s19. PMID: 34491030 / doi: 10.36849/jdd.6229
  30. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian Skin Management in Oncology (CaSMO) Algorithm for Patients With OncologyTreatment-Related Skin Toxicities. Skin Therapy Lett 2021 Mar Suppl
  31. Sauder MB, Addona M, AndriessenA, Butler M, Claveau J, Feugas N, Hijal T, Iannattone L, Kalia S, Teague L, Lynde CW. The Role of Skin Care inOncology Patients. Skin Therapy Lett 2020 Oct
  32. Lynde C, Tan J, Andriesse A, Skotnicki S, Beecker J, ClaveauJ, Li MK, Rao J, Salsberg J, Sauder MB, Zip C. Clinical Insights About the Role of pH in Acne. J Drugs Dermatol 2019 Dec 1; 18(12): 221.PMID: 31860223
  33. Lynde C, Tan J, Skotnicki S, Beecker J, Claveau J, Li MK, Rao J, Salsberg J, Sauder MB,Zip C. Skin Surface pH. J Drugs Dermatol 2019 Dec 1; 18(12): 214. PMID: 31860222
  34. Shelley AJ, McDonaldKA, McEvoy A, Sauder M, Kanigsberg N, Zemek R, Vaillancourt R, Pouliot A, Ramien ML. Usability,Satisfaction, and Usefulness of an Illustrated Eczema Action Plan. J Cutan Med Surg 2018 Nov/Dec; 22(6): 577-582. Epub 2018 Jul 13. PMID: 30003800 / doi: 10.1177/1203475418789028
  35. McEvoy A, Sauder MB, McDonald K, Suter P, Pouliot A, Zemek R, Kanigsberg N, Vaillancourt R, Ramien ML. Evaluation,and Validation of Illustrations of Key Counselling Points for a Pediatric Eczema Action Plan. J Cutan Med Surg2018 Mar/Apr; 22(2): 147-153. Epub 2017 Nov PMID: 29098866 / doi: 10.1177/1203475417741260
  36. Sauder MB, O’Malley JT, LeBoeuf NR. CD30+ Lymphoproliferative Disorders of the Skin. Hematol Oncol Clin North Am 2017 Apr; 31(2):317-334. PMID: 28340881 / doi: 10.1016/j.hoc.2016.11.006
  37. Sauder MB, McEvoy A, Ramien ML. Prescribing success: Developing an integrated prescription and eczema action planfor atopic dermatitis. J Am Acad Dermatol 2016 Dec; 75(6): 1281-1283./ doi: 10.1016/j.jaad.2016.08.029
  38. Burd D, Sauder MB, Beecker J. Yellow plaques in a patient with livercirrhosis. J Am Acad Dermatol 2016 Apr; 74(4): e57-e58. doi: 10.1016/j.jaad.2015.09.068
  39. Mani N, ManiM, Sauder D, Sauder MB and Bothwell MR. Update of Novel Use of Polymethyl Methacrylate (PMMA)Microspheres in the Treatment of Infra-Orbital Rhytids. Austin J Dermatolog 2016; 3(5): 1062-pp.
  40. WoolnerK, Sauder M. Periorbital erythema following alcohol ingestion during treatment with topical tacrolimus. CMAJ 2016 Mar 15; 188(5): 368. Epub 2015 Nov 23. PMID: 26598374 / doi:10.1503/cmaj.150710
  41. Sauder MB, McEvoy A, Sampson M, Kanigsberg N, Vaillancourt R, Ramien ML,Zemek R. The Effectiveness of Written Action Plans in Atopic Dermatitis. Pediatr Dermatol 2016 Mar-Apr; 33(2): e151-3. Epub 2016 Jan 17. PMID: 26776967 / doi: 10.1111/pde.12774
  42. Sauder MB, Pratt MD. Acrylate Systemic Contact Dermatitis. Dermatitis 2015 Sep-Oct; 26(5): 235-8. PMID: 26367207 / doi: 10.1097/DER.0000000000000136
  43. Sauder MB, Cheung L, Beecker J. Acitretin-induced hepatitis: when to monitor cholestatic enzymes. J CutanMed Surg 2015 Mar-Apr; 19(2): 115-20. Epub 2015 Mar 11. PMID: 25775629 / doi:10.2310/7750.2014.14051
  44. Sauder MB, Linzon-Smith J, Beecker J. Extragenital bullous lichen sclerosus. J Am Acad Dermatol 2014 Nov; 71(5): 981-4. Epub 2014 Jul 31. PMID: 25088813 / doi:10.1016/j.jaad.2014.06.037
  45. Jacobson D, Hollinger S, Seelisch J, Sauder M, MacCormick J, Ferretti E. Case1: A premature infant with stridor. Paediatr Child Health 2014 Oct; 19(8): 401-2. PMID: 25382992
  46. SauderMB, Beecker J, Ramsay T. Comment on ‘A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis’. J Am Acad Dermatol 2014 May; 70(5): 950-1. PMID: 24742841 /doi: 10.1016/j.jaad.2013.08.058
  47. Mani N, McLeod J, Sauder MB, Sauder DN, Bothwell MR. Novel use of polymethyl methacrylate (PMMA) microspheres in the treatment of infraorbital rhytids. J CosmetDermatol 2013 Dec; 12(4): 275-80. PMID: 24305426 / doi: 10.1111/jocd.12065
  48. Sauder MB, Glassman SJ.Palmoplantar subcorneal pustular dermatosis following adalimumab therapy for rheumatoid arthritis. Int JDermatol 2013 May; 53(5): 624-8. Epub 2013 Mar 14. PMID: 23489057 / doi: 10.1111/j.1365-4632.2012.05707.x
  49. Sauder DN, Sauder MB. Molecular mechanisms in psoriasis: historical perspective andcurrent pathogenesis. Expert Rev Dermatol 2013 Feb; 8(1): 1-3. Epub 2014 Jan 10. doi: 10.1586/edm.12.77
  50. Robertson L, Sauder MB. Basal Cell Carcinoma in Type 2 Segmental Darier’s Disease. J Skin Cancer 2012;2012: 839561. Epub 2011 Jul 31. PMID: 21826272 / doi: 10.1155/2012/839561
  51. Sauder MB. The H1N1 birthday cake: To blow or not to blow. CMAJ 2010 Mar 9; 182(4): 384. PMID: 20212056 / doi: 10.1503/cmaj.110-2032

Other Professional/Academic Activities

  • Organizing Faculty Member, Canadian Melanoma Conference (2023-Present)
  • Medical Advisor, Canadian Association of Psoriasis Patients
  • Medical Advisor, Look Good Feel Better
  • Fellowship Director, Cutaneous Oncology, Department of Medicine, University of Toronto
Dr. Juthika Thakur – Regional Director, Ontario (Election)

Dr Thakur

 

Present Affiliations

 Academic

  • Lecturer, McMaster University (Clerkship Review Program, Internal Medicine Resident Academic Half Days)

Clinical

  • Dermatologist, Canadian Dermatology Centre Dermatologist and Advisor, Skinopathy
  • Principal Investigator, A prospective, observational study of Canadian patients receiving Dupixent for moderate to severe atopic dermatitis

CDA Involvement

  •  Artificial Intelligence Subcommittee Member

Other National, Provincial and Local Dermatology Societies

  • American Academy of Dermatology, Fellow
  • European Academy of Dermatology and Venereology, Member

Other Professional/Academic Activities

  • Technology and Dermatology Advisor, AIPLabs
  • NAC OSCE Examiner Medical Council of Canada – Ottawa, Ontario
  • Residency OSCE Examiner Division of Dermatology, University of Toronto – Toronto, Ontario
  • Co-Chair, World Congress of Digital Health in Dermatology
  • Co-Chair, DermInsight Symposium

Number Of Publications Authored

6

List of Publications Authored

  1. Thakur Perspectives, and insights on Tildrakizumab: Tildrakizumab in PsA – a data review. CanadianDermatology Today. Sun Pharma. Sep 2021.
  2. Neal N, Thakur The Big Pharma Bust: The collapse of Western pharmaceutical companies isinevitable. Ivey Business Review, 2010. Vol 1. Issue 1. Apr 2010

Posters/Abstracts/Oral Presentations

  1. Thakur J, Review of a successful pilot demonstrating integration of computer vision and language modelsin the circle of care for dermatology patients in a teledermatology clinic in Hungary. [Oral Presentation] 25thWorld Congress of Dermatology, Singapore, Jul
  2. Thakur J, Perspectives on artificial intelligence in the field of dermatology – real world application of AIsolution as a pilot project in Budapest, [Oral Presentation] 9th World Congress ofTeledermatology, Remote, Dec 2021
  3. Thakur J, Evaluating artificial intelligence in [Poster Presentation] EADV Barcelona, Spain, Dec 2019.
  4. Thakur J, Walsh S, IgA Pemphigus – A novel classification, a review of the [Poster Presentation] EADV Conference Paris, France, Sep 2018.
  5. Thakur J, Walsh IgA Pemphigus – A novel classification. [Oral Presentation] The Canadian Dermatology Association. Toronto, Canada, Jun 2018.
  6. Thakur J, Agarwal S, Lima, H, Photodermatitis as an initial presentation of common variableimmunodeficiency. [Poster Presentation] World Congress of Dermatology, Vancouver, British Columbia, Jun 2015.
Dr. Laurie Parsons – Regional Director, Prairie Provinces (Acclaimed)

Dr ParsonsPresent Affiliations

Academic

  • Clinical Associate Professor University of Calgary

Clinical

  • Contact Dermatitis Wound Healing RPC committee member for the University of Calgary Dermatology Residency Program

CDA Involvement

Present:

  • Education Committee
  • EDI Committee

Annual Conference Committee Past:

  • Board member

Other National, Provincial and Local Dermatology Societies

  • AAD member
  • ACDS member
  • Faculty for IIWCC

Medical Society, Governmental and/or Professional Appointments, Awards and Honours

  • Medical Director Sheldon Chumir Wound Clinic

Number of Publications Authored

57

List of Publications Authored 

  1. “Papp, Kim A; DeKoven, Joel; Parsons, Laurie; Pirzada, Syed; Robern, Michael; Robertson, Lynne; Tan,Jerry KL; “,Biologic therapy in psoriasis: perspectives on associated risks and patient management,Journal ofCutaneous Medicine and Surgery,16,3,153- 168,2012,”SAGE Publications Sage CA: Los Angeles, CA”
  2. “Parsons, Laurie M; “,Glyceryl monothioglycolate,DERM,19,6,E51-E52,2008,Decker Medicine
  3. “Parsons, LM; “,Two Cases of Unusual Intra-oral Reactions to Cinnamic Aldehyde,DERM,19,3,172-172,2008,Decker Medicine
  4. “Parsons, Laurie M; “,The Role of Quaternium-15 in Occupational Dermatitis,DERM,19,6,357-357,2008,Decker Medicine
  5. “Parsons, Laurie M; “,Cocamidopropyl betaine,DERM,19,6,E49-E50,2008,Decker Medicine
  6. “Parsons, Laurie M; “,Pitfalls in the diagnosis of chronic osteomyelitis in the presence of a contiguousneuropathic ulcer,Journal of Cutaneous Medicine and Surgery,13,3_suppl,S35-S37,2009,”SAGEPublications Sage CA: Los Angeles, CA”
  7. “Guo, Danny; Parsons, Laurie M; “,Sweet syndrome in a patient with chronic hepatitis C,Journal ofCutaneous Medicine and Surgery,18,6,436-468,2014,”SAGE Publications Sage CA: Los Angeles, CA”
  8. “Wong, Noelle Y; Parsons, Laurie M; Trotter, Martin J; Tsang, Roger Y; “,Drug-induced subacute cutaneouslupus erythematosus associated with docetaxel chemotherapy,,,,,,
  9. “Wong, Noelle Y; Parsons, Laurie M; Trotter, Martin J; Tsang, Roger Y; “,Drug-induced subacutecutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report,BMC Research Notes,7,,1-5,2014,BioMed Central
  10. “Isaac-Renton, Megan; Li, Monica Kayi; Parsons, Laurie M; “,Cinnamon spice and everything notnice: many features of intraoral allergy to cinnamic aldehyde,Dermatitis,26,3,116-121,2015,Ovid Technologies (Wolters Kluwer)-Lippincott Williams & Wilkins
  11. “Parsons, Laurie M; “,What’s Trending,,,,,,
  12. “Botros, M; Goettl, K; Parsons, L; Menzildzic, S; Morin, C; Smith, T; Hoar, A; Nesbeth, H; McGrath, S; “,”Best practice recommendations for the prevention, diagnosis and treatment of diabetic foot ulcers: update2010”,Wound Care Canada,8,4,6-70,2010,
  13. “Lewinson, Ryan T; Vallerand, Isabelle A; Lowerison, Mark W; Parsons, Laurie M; Frolkis, Alexandra D;Kaplan, Gilaad G; Bulloch, Andrew GM; Swain, Mark G; Patten, Scott B; Barnabe, Cheryl; “,Depression isassociated with an increased risk of psoriatic arthritis among patients with psoriasis: a population-basedstudy,Journal of Investigative Dermatology,137,4,828-835,2017,Elsevier
  14. “Lewinson, Ryan; Vallerand, Isabelle; Lowerison, Mark; Parsons, Laurie; Frolkis, Alexandra; Kaplan,Gilaad; Bulloch, Andrew; Patten, Scott; Barnabe, Cheryl; “,Depression and the Risk of Psoriatic ArthritisAmong Patients with Psoriasis: A Population-Based Cohort Study,ARTHRITIS & RHEUMATOLOGY,68,,,2016,”WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA”
  15. “Vallerand, IA; Lewinson, RT; Parsons, LM; Lowerison, MW; Frolkis, AD; Kaplan, GG; Barnabe, C; Bulloch,AGM; Patten, SB; “,Risk of depression among patients with acne in the UK: a population-based cohortstudy,British Journal of Dermatology,178,3,e194- e195,2018,”Blackwell Publishing Ltd Oxford, UK”
  16. “Vallerand, IA; Lewinson, RT; Parsons, LM; Lowerison, MW; Frolkis, AD; Kaplan, GG; Barnabe, C;Bulloch, AGM; Patten, SB; “,Is depression screening in patients with acne critical?: reply fromauthors,The British journal of dermatology,179,1,227-228,2018,
  17. “Lewinson, Ryan T; Vallerand, Isabelle A; Parsons, Laurie M; LaMothe, Jeremy M; Frolkis, Alexandra D;Lowerison, Mark W; Kaplan, Gilaad G; Patten, Scott B; Barnabe, Cheryl; “,Psoriasis and the risk of foot andankle tendinopathy or enthesopathy in the absence of psoriatic arthritis: a population-based study,RMDOpen,4,1,e000668,2018,BMJ Specialist Journals
  18. “Cinats, Allison K; Parsons, Laurie M; Haber, Richard M; “,Facial involvement in dermatitisherpetiformis: a case report and review of the literature,Journal of Cutaneous Medicine andSurgery,23,1,35-37,2019,”SAGE Publications Sage CA: Los Angeles, CA”
  19. “Lewinson, Ryan; Vallerand, Isabelle; Parsons, Laurie; LaMothe, Jeremy; Frolkis, Alexandra;Lowerison, Mark; Kaplan, Gilaad; Bulloch, Andrew; Patten, Scott; Barnabe, Cheryl; “,Psoriasis and the risk of foot and ankle tendinopathy or enthesopathy: A population-basedstudy,JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,79,3,AB233-AB233,2018,”MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA”
  20. “Vallerand, Isabelle; Lewinson, Ryan; Parsons, Laurie; Lowerison, Mark; Frolkis, Alexandra; Kaplan,Gilaad; Barnabe, Cheryl; Bulloch, Andrew; Patten, Scott; “,Risk of depression among patients with acne: Apopulation-based cohort study using The Health Improvement Network (THIN) database,JOURNAL OF THEAMERICAN ACADEMY OF DERMATOLOGY,79,3,AB247-AB247,2018,”MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA”
  21. Lewinson, Ryan T; Vallerand, Isabelle A; LaMothe, Jeremy M; Parsons, Laurie M; Frolkis, AlexandraD; Lowerison, Mark W; Patten, Scott B; Barnabe, Cheryl; “,Increasing rates of arthroplasty for psoriaticarthritis in the United Kingdom between 1995 and 2010,Arthritis Care & Research,71,11,1525-1529,2019,
  22. “Botros, M; Kuhnke, J; Embil, J; Goettl, K; Morin, C; Parsons, L; Scharfstein, B; Somayaji, R; Evans, R;”,Best prac-tice recommendations for the prevention and management of diabetic foot ulcers In: Foundationsof Best Practice for Skin and Wound Manage-ment,A supplement of Wound Care Canada,,,,2017,
  23. Vallerand, Isabelle A; Lewinson, Ryan T; Parsons, Laurie M; Hardin, Jori; Haber, Richard M; Lowerison,Mark W; Barnabe, Cheryl; Patten, Scott B; “,Vitiligo and major depressive disorder: A bidirectional population-based cohort study,Journal of the American Academy of Dermatology,80,5,1371-1379,2019,Mosby
  24. “Vallerand, Isabelle A; Lewinson, Ryan T; Parsons, Laurie M; Hardin, Jori; Haber, Richard M; Lowerison,Mark W; Barnabe, Cheryl; Patten, Scott B; “,Assessment of a bidirectional association between majordepressive disorder and alopecia areata,JAMA dermatology,155,4,475-479,2019,American MedicalAssociation
  25. “Shukalek, Caley; Parsons, Laurie; Somayaji, Ranjani; “,Delving into skin and soft tissue infections (SSTI)Part II: Focus on superficial infections,World Council of Enterostomal Therapists Journal,37,3,20-24,2017,
  26. “Rodriguez-Arguello, Jimena; Lienhard, Karin; Patel, Pooja; Geransar, Rose; Somayaji, Ranjani; Parsons,Laurie; Conly, John; Ho, Chester; “,A scoping review of the use of silver-impregnated dressings for the treatment of chronic wounds,Ostomy Wound Manage,64,3,14-31,2018,
  27. “Mydlarski, P Régine; Parsons, Laurie M; Pierscianowski, Tadeusz A; Humphrey, Shannon; Kirchhof,Mark G; Powell, Julie; Rosen, Cheryl F; Huck, Emma; Conway, Josée; Kouri, Adam; “,Dermatologic trainingand practice in Canada: a historical overview,Journal of Cutaneous Medicine and Surgery,23,3,307-318,2019,”SAGE Publications Sage CA: Los Angeles, CA”
  28. “Dupuis, Elaine; Zarbafian, Misha; Asgarpour, Jessica; Parsons, Laurie; Mydlarski, P Régine;”,Plasmablastic-like lymphoma arising within chronic pyoderma gangrenosum,JAAD casereports,3,3,200-201,2017,Elsevier
  29. “Botros, Mariam; Kuhnke, J; Embil, J; Goettl, K; Morin, C; Parsons, L; Scharfstein, B; Somayaji, R;Evans, R; “,Prevention and management of diabetic foot ulcers,Canadian Association of Wound Care(Wounds Canada),,,,2019,
  30. “Mourad, Ahmed; Nurmohamed, Sabrina; Parsons, Laurie; “,Metal hypersensitivity to orthopedic implants,Dermatitis,30,4,278-280,2019,Ovid Technologies (Wolters Kluwer)- Lippincott Williams & Wilkins
  31. “Woo, Taylor E; Somayaji, Ranjani; Haber, RM; Parsons, Laurie; “,Diagnosis and management ofcutaneous tinea infections,Advances in Skin & Wound Care,32,8,350- 357,2019,LWW
  32. “Traboulsi, Danya; Hardin, Jori; Parsons, Laurie; Waechter, Jason; “,Does self- modulated learning algorithm-regulated learning of dermatology morphology affect learning efficiency of medicalstudents?,Canadian Medical Education Journal,10,3,e82,2019,
  33. “Vallerand, IA; Lewinson, RT; Parsons, LM; Hardin, J; Haber, R; Lowerison, MW; Barnabe, C; Patten, SB;”,Bidirectional association between major depressive disorder and alopecia areata: A population-basedstudy,JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY,81,4,AB26-AB26,2019,”MOSBY-ELSEVIER 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA”
  34. “Woo, Taylor E; Somayaji, Ranjani; Haber, RM; Parsons, Laurie; “,Scratching the surface: A review ofdermatitis,Advances in Skin & Wound Care,32,12,542-549,2019,LWW
  35. “Kirchhof, Mark G; Parsons, Laurie M; Pierscianowski, Tadeusz A; Humphrey, Shannon; Powell, Julie;Rosen, Cheryl F; Mydlarski, P Régine; “,Dermatologic Training and Practice in Canada: a historical overview—author response,Journal of Cutaneous Medicine and Surgery,24,1,105-106,2020,”SAGE Publications SageCA: Los Angeles, CA”
  36. “Mydlarski, P Régine; Parsons, Laurie M; Pierscianowski, Tadeusz A; Kirchhof, Mark G; Rosen, Cheryl F;Purdy, Kerri; Powell, Julie; Humphrey, Shannon; Clermont, Megan; Elliot, Shannon; “,Dermatologic trainingand practice in Canada: an in-depth review,Journal of Cutaneous Medicine and Surgery,24,3,297-303,2020,”SAGE Publications Sage CA: Los Angeles, CA”
  37. “Vallerand, IA; Lewinson, RT; Parsons, LM; Lowerison, MW; Patten, SB; Barnabe, C; “,Depression as arisk factor for the development of psoriasis: a retrospective cohort study in the UK,British Journal ofDermatology,183,4,776-778,2020,”Blackwell Publishing Ltd Oxford, UK”
  38. “Vallerand, Isabelle; Lewinson, Ryan; Parsons, Laurie; Lowerison, Mark; Patten, Scott B; Barnabe, Cheryl;”,16742 Depression as a risk factor for the development of psoriasis,Journal of the American Academy ofDermatology,83,6,AB69,2020,Elsevier
  39. “Kuzyk, Alexandra; Zhang, Connie; Parsons, Laurie; “,27328 The impact of a dedicated wound clinic onwound healing,Journal of the American Academy of Dermatology,85,3,AB31,2021,Elsevier
  40. “Kuzyk, A; Zhang, C; Parsons, L; “,636 Factors associated with prolonged wound healing,Journal ofInvestigative Dermatology,141,5,S110,2021,Elsevier
  41. “Hughes, JD Matthew; Vallerand, Isabelle; Lewinson, Ryan; Parsons, Laurie; “,28527 A Canada widesurvey of access to patch testing,Journal of the American Academy of Dermatology,85,3,AB195,2021,Elsevier
  42. “Burma, Nicole E; Woo, Taylor E; Parsons, Laurie; “,Topical Clascoterone for Acne ,SkinTherapy Letter,27,1,1-3,2022,
  43. “Voegeli, David; “,Prevention and management of moisture-associated skin , NursingStandard,34,2,,2019, ,
  44. BEST PRACTICE RECOMMENDATIONS FOR THE Prevention and Management of Moisture-associated Skin Damage,,,,,,
  45. “Pooja Patel, MBT; Ranjani Somayaji, MD; Laurie Parsons, MD; John Conly, MD; Chester Ho, MD; “,ScopingReview of the Use of Silver-Impregnated Dressings for the Treatment of Chronic Wounds,Microbiology,3,1,9,, ,
  46. BEST PRACTICE RECOMMENDATIONS FOR THE Prevention and Management of Moisture-associated Skin Damage,Wounds Canada Publication,,,,2020,
  47. “Parsons, Laurie M; “,What Is the Role of Allergic Contact Dermatitis in Patients with Lower LegUlcers?,Advances in Skin & Wound Care,36,7,348-354,2023,LWW
  48. “Hardin, Jori; Mourad, Ahmed; Desy, Janeve; Paget, Mike; Ma, Irene; Traboulsi, Danya; Johnson, Nicole A;Ali, Asma Amir; Parsons, Laurie; Harvey, Adrian; “,Mitigating diagnostic performance bias in a skin-tonebalanced dermatology curriculum,The Clinical Teacher,20,6,e13613,2023,
  49. “Alkhaleefa, Ayaa; Woo, Taylor Evart; Parsons, Laurie; “,Dupilumab for the Treatment of Prurigo,Skin Therapy Letter,28,6,7-9,2023,
  50. “Rodriguez-Arguello, Jimena; Lienhard, Karin; De Grood, Jill; Geransar, Rose; Somayaji, Ranjani; Khan,Daniyal; Conly, John; Ho, Chester; Parsons, Laurie; “,The Use of Silver Oxynitrate Wound Dressings in theTreatment of Chronic Wounds: A Feasibility Pilot Study,Advances in Skin & WoundCare,,,10.1097,2022,LWW
  51. “Lukmanji, Aysha; Vallerand, Isabelle A; Lewinson, Ryan T; Hughes, JD Matthew; Parsons, LaurieM; “,Challenges and Benefits to Patch Testing for Allergic Contact Dermatitis: A Canadian PatientPerspective,Journal of Cutaneous Medicine and Surgery,28,3,297-298,2024,”SAGE Publications Sage CA: Los Angeles, CA”
  52. “Wytsma, Jennifer; Woo, Taylor Evart; Parsons, Laurie; “,Long-Term Efficacy of Tildrakizumab in the Treatment of Psoriasis.,Skin Therapy Letter,29,3,5-8,2024,
  53. “Lukmanji, Aysha; Vallerand, Isabelle A; Lewinson, Ryan T; Hughes, J D Matthew; Parsons, Laurie M;”,Patch Testing Delivery: A Cross-Sectional Inquiry into the Experiences of Patch TestingDermatologists,Dermatitis®,,,,2024,”Mary Ann Liebert, , publishers 140 Huguenot Street, 3rd Floor New…”
  54. “Adly, Merna; Ladha, Malika A; Mydlarski, Régine; Petrasek, Paul; Parsons, Laurie; “,Painlessulceration due to digital hypoperfusion ischaemic syndrome: case report and literature review,Journal ofWound Care,32,Sup7,S26-S30,2023,MA Healthcare London
  55. “Park, Ye-Jean; Ma, Bryan; Jia, Jocelyn; Parsons, Laurie; “,Temporal and regional trends in Canada for theepidemiology and management of diabetic foot ulcers,Journal of Wound Care,33,11,856-864,2024,MAHealthcare London
  56. “Juster, Thomas; Hill, Martha; Stafford, Frank; Parsons, L; “,”Time Use Longitudinal Panel Study, 1975-1981:Vol Users’ Guide”,”Ann Arbor, MI: Inter-University Consortium for Political and Social Research”,,,,1983,
  57. “Ma, Bryan; Gandhi, Maharshi; Czyz, Sonia; Jia, Jocelyn; Rankin, Brian; Osman, Selena; Jonsson, EvaLindell; Robertson, Lynne; Parsons, Laurie; Temple-Oberle, Claire; “,Risk Prediction Models for Sentinel NodePositivity in Melanoma: A Systematic Review and Meta-Analysis,JAMA Dermatology,,,,2025,
Dr. Stéphanie Turmel – Regional Director, Quebec (Acclaimed)

Dr. Turmel

 

Present Affiliations

Academic

  • Student, extern and resident supervising physician; Faculty of Medicine, Université Laval – 2022 to present

Clinical

  • Dermatologist, Clinique Saint-Louis – Dermatologie, July 2021 to present
  • Centre dermatologique du Québec Métropolitain (CDQM), September 2015 to June 2021
  • Investigator, Centre de recherche Saint-Louis

CDA Involvement

  • Four-monthly collaborator to the CDA Bulletin, 2012-2015
  • Outreach publications for Canadian colleagues regarding the Québec University DermatologyProgram

Other National, Provincial and Local Dermatology Societies

  • Secretary, Société de Dermatologie de Québec, April 2024 to present

Medical Society, Governmental and/or Professional Appointments, Awards and Honours

  • Member of the jury and dermatology examiner for the Royal College of Physicians and Surgeons of Canada, December 2023 to present
  • Member of the Pedagogy Committee, Fédération des Médecins Spécialistes du Québec (FMSQ),December 2024 to present

Other Professional/Academic Activities

Presentations:

  • Presentation at the Canadian Dermatology Association Annual conference, Pediatrics, June 2013
  • Clinical Pearls for Biotherapies, Québec, January 2017, AbbVie
  • Dermatology Year in Review, Toronto, March 2017, Lilly
  • Psoriasis Year in Review, Quebec, June 2017, Lilly
  • Psoriasis Year in Review, Montreal, October 2017, Lilly
  • Managing Psoriasis, Physicians, Family Medical Clinic, St-Agapit, February 2018, Janssen, Leo pharma
  • Étude CAFÉ-ADvantage Program at AAD, San Diego, February 2018, Sanofi Genzyme
  • Panel moderator, Family Physicians, Québec, October 2018, Bausch-Health
  • Atopic Dermatitis, Sainte-Foy Pediatric Clinic, October 2018, Leo Pharma
  • Rosacea in Detail, FMOQ, October 2018, Galderma
  • Psoriasis Treatment Diagnostic Update, GMF, December 2018, Bausch-Health
  • Dermatology for the General Pactitioner, AMOQ, February 2019, Bausch-Health
  • Atopic Dermatitis, AMOQ, May 2019, Pfizer
  • Presentation, CLEAR Program, CDQM, June 2019, Lilly
  • Dermatology Case Reports, Quebec, November 2019, Celgene
  • Winter Clinical Dermatology Conference in Review, Quebec, February 2020, AbbVie
  • Atopic Dermatitis, Case Reports and Clinical Pearls, Polyclinique de la Capitale, March 5, 2020 Pfizer
  • Dermatology Panel, Quebec City, June 2020, AbbVie
  • IMMhance and IMMerge Review, CDQM, September 2020, AbbVie
  • An Hour with my Dermatologist, video conference, November 2020, Bausch-Health
  • Open Horizons Program Review, video conference, February 2021, AbbVie
  • Difficult-to-Treat Areas in Psoriasis, CDQM, March 2021, AbbVie
  • AAD’s VMX Review, June 2021, Centre Dermatologique du Québec Métropolitain, AbbVie
  • Moderator, Canadian Dermatology Association Annual Conference, June 2022, Oncology session, June 2022
  • Potpourri in Dermatology, presentation for family physicians, Clinique St-Louis, May 2023
  • Presentation of the 2023 Étoile Program, Novartis, Paris, December 2023
  • Conference Review, Incyte, National Committee, San Diego, March 2024
  • Congress Review, SunPharma, National Committee, San Diego, March 2024
  • Moderator, Provincial Conference on the Prevention of Infections through Vaccination inImmunosuppressed Patients, March 2024, Abbvie
  • DuTell Academy Training Review, June 2024
  • Moderator, Abbvie Psoriasis Advisory Meeting, May 2024
  • Conference on Clinic Optimization, “How can we optimize our dermatology clinic to be more efficient?” September 2024
  • Dermoscopy Excellence Conference Review, September 2024, UCB
  • Moderator and host, Psoriasis Advisory Meeting, Bausch-Health, November 2024
  • Speaker, Dermatology Dialogue, Bausch-Health, January 2025
  • Moderator, Johnson&Johnson Psoriasis Advisory Meeting, January 2025
  • Speaker, Psoriasis and its Imitators, GMF Neuville, February 2025

Programs:

  • Chair, GENIES Scientific Committee (Effective Guide to Interdisciplinary Concepts for Specific Issues,Biological Therapies and Collaboration with Other Specialties for the Treatment of Shared Patients),August 2024 to present,
  • UCB – Member of the Scientific Committee, creating content for “New Mechanisms of Action in theTreatment of Atopic Dermatitis”, Lilly, 2025
  • Member of the HS-PsO Derm Clinic Reference Tools project, Novartis, 2024-2025
  • Canadian Psoriasis Patient Charter Creation Committee, Toronto, September 2024 to present, Johnson&Johnson

Event Organization:

  • CDQM Monthly Reading Clubs, CDQM, 2018-2019, Janssen-Sanofi
  • Training of Medical Personnel on the EASI Index, CDQM, October 2018
  • CDQM Reading Clubs, February 2021-June 2021, Bausch-Health
  • Creator, organizer and moderator for the Dermatology and First Nations Provincial Conference. Better Understanding Issues to Improve Care, October 2022
  • Creator, organizer and moderator, Provincial presentation, Gender diversity: gender transition,discussion on medical and psychosocial September 2023, Moderator and organizer,Identifying Immunodeficiency in Dermatology Conference, Feb. and Nov. 2023
  • Creator, organizer and moderator, provincial presentation, Dealing with Fatphobia in the MedicalField, “Body Weight and Health: Caring with Science”, May 2023, UCB
  • Member, Beyond the Skin project, organizing scientific committee, 2023 to present, Janssen
  • Creator, organizer and moderator, Genital Dermatoses Provincial Conference, November 2023, UCB
  • Creator and moderator, “Let’s Talk to an Expert: The Risk of Melanoma Associated with Biological andAnti-JAK agents + Management of Immunotherapy-Induced Psoriasis and Eczema”, ProvincialConference, June 2024, Abbvie Philanthropy: volunteer, ÉLAN Foundation, 2011 to present
  • Involvement in fundraising activities for the Fondation de l’Institut de réadaptation en déficience physique de Québec (Quebec Rehabilitation Institute for the Physically Disabled) (Annual golf tournament, California Wine Festival, Apple campaign)
  • Volunteer caregiver, Camp Liberté, Summer 2013; Care and support for children with skin conditions at the summer camp